
- Past Issues
- e-Submission
-
2021 Impact Factor 1.766
5-Year Impact Factor 1.674
Editorial Office
- +82-01-9989-7744
- kbiolpsychiatry@gmail.com
- https://www.biolpsychiatry.or.kr/
2021 Impact Factor 1.766
5-Year Impact Factor 1.674
Korean Journal of Biological Psychiatry 1996;3(2):269-76. Published online: Feb, 1, 1996
Object :
The aim of this study was to examine an association between plasma 5-Hydroxyindoleacetic Acid(HIAA) level and the change of depressive symptom after fluoxetine trial in haloperidol-stabilized schizophrenic in-patients.
Method : According to plasma 5-HIAA level, 32 patients were classified to either group with high 5-HIAA level(N=11) or that with low 5 HIAA(N=11). For each patient, fluoxetine(20mg/day) added to stable haloperidol dose for 6 weeks. The authors measured Hamilton Rating Scale for Depression(HRSD) at baseline, the 2nd week, the 4th week, the 6th week of treatment.
Result : 1) Age, duration of illness, number of admission, duration of present admission, dosage of haloperidol between high 5-HIAA group and low 5-HIAA group were significantly different. 2) As time went on, the association between the change of depressive symptom and plasma 5-HIAA concentration was not significant. 3) Of depressed group, as time went on, depressive symptoms were improved significantly in high 5-HIAA group, but not in low 5-HIAA group.
Conclusion : We suggest that the association between plasma 5-HIAA level and the change of depressive symptoms after fluoxetine trial in haloperidol stabilized schizophrenic in-patinets was not significant.
Keywords Schizophrenia;5-HIAA;Fluoxetine;HRSD.